文献速递脊柱关节炎

靶向IL17A的肽基疫苗减轻HLA-B27转基因大鼠的实验性脊柱关节炎

Peptide-based vaccine targeting IL17A attenuates experimental spondyloarthritis in HLA-B27 transgenic rats.
PubMed 文献 · RMD Open · 2023-01-01

研究在HLA-B27/hβ2M转基因大鼠中用热灭活结核分枝杆菌诱导脊柱关节炎模型,三次免疫IL17A肽基疫苗(铝佐剂)后成功诱导抗体产生,并抑制关节炎评分、关节厚度、附着点炎、骨破坏和新骨形成,且未引发IL17A反应性T细胞;在治疗模型中疫苗有减轻趋势但无统计学显著性。

要点

  • IL17A肽基疫苗可诱导抗体产生并抑制实验性脊柱关节炎的关节炎评分和关节厚度。
  • X线和组织学分析显示疫苗抑制附着点炎、骨破坏和新骨形成。
  • ELISpot未检测到IL17A反应性T细胞应答;治疗模型中疫苗有减轻趋势但无统计学显著性。

核心结论

  • 靶向IL17A的肽基疫苗可减轻热灭活结核分枝杆菌诱导的HLA-B27/hβ2M转基因大鼠脊柱关节炎表型。
  • 作者认为IL17A肽基疫苗可能成为脊柱关节炎的治疗选择。

研究设计与样本

  • 在HLA-B27/hβ2M转基因大鼠中用热灭活结核分枝杆菌免疫建立脊柱关节炎和关节炎的实验模型。
  • 大鼠接受钥孔血蓝蛋白偶联的IL17A肽基疫苗(铝佐剂)免疫三次。
  • 用ELISA评估IL17A抗体滴度,每周两次监测关节炎评分和关节厚度。
  • 用酶联免疫斑点(ELISpot)检测分泌IL4和干扰素-γ的脾细胞以评估IL17A特异性T细胞活化。
  • 另在脊柱关节炎治疗模型中评估IL17A疫苗的效果。

主要发现

  • IL17A肽基疫苗(铝佐剂)成功诱导抗体产生,并抑制关节炎评分和关节厚度。
  • X线和组织学分析显示IL17A疫苗抑制附着点炎、骨破坏和新骨形成。
  • ELISpot显示IL17A肽基疫苗未引发任何IL17A反应性T细胞应答。
  • 在脊柱关节炎治疗模型中,IL17A疫苗有减轻趋势但无统计学显著性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Spondyloarthritis (SpA) is known as series of immune-mediated inflammatory disease of the axial and peripheral joints. Human leucocyte antigen (HLA)-B27 is a genetic risk factor for SpA. Recent evidence suggests that the interleukin -17 (IL17) axis strongly contributes to SpA. This study aimed to assess the efficacy of an IL17A peptide-based vaccine on SpA manifestations in model rats. METHODS: HLA-B27/human β2-microglobulin (hβ2M) transgenic rats were immunised with heat-inactivated Mycobacterium tuberculosis (MT) to develop spondylitis and arthritis as an experimental SpA model after immunisation with a keyhole limpet hemocyanin-conjugated IL17A peptide-based vaccine with an alum adjuvant three times. The IL17A antibody titre was assessed using ELISA, and arthritis score and joint thickness were monitored two times a week. Enzyme-linked immunospot (ELISpot) assays for IL4- and interferon-γ-secreting splenocytes were conducted to evaluate IL17A-specific T cell activation. We also evaluated the effect of IL17A vaccine in SpA therapeutic model. RESULTS: The IL17A peptide-based vaccine with alum adjuvant successfully induced antibody production and suppressed the arthritis score and joint thickness. X-ray and histological analyses showed that enthesitis, bone destruction and new bone formation were inhibited by the IL17A vaccine. The ELISpot assay showed that the IL17A peptide-based vaccine did not elicit any IL17A-reactive T cell responses. IL17A vaccine tends to mitigate, but not significant, in SpA treatment model. These data showed that the peptide-based vaccine targeting IL17A alleviated the SpA phenotype in a heat-inactivated MT-induced SpA model in HLA-B27/hβ2M transgenic rats. CONCLUSIONS: IL17A peptide-based vaccine may be a therapeutic option for SpA treatment.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Hayashi H, Sun J, Yanagida Y, et al. Peptide-based vaccine targeting IL17A attenuates experimental spondyloarthritis in HLA-B27 transgenic rats. RMD Open. 2023. PMID: 36737108. doi:10.1136/rmdopen-2022-002851

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。